1
|
Haufe Y, Loser D, Danker T, Nicke A. Symmetrical Bispyridinium Compounds Act as Open Channel Blockers of Cation-Selective Ion Channels. ACS Pharmacol Transl Sci 2024; 7:771-786. [PMID: 38495220 PMCID: PMC10941285 DOI: 10.1021/acsptsci.3c00308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 01/12/2024] [Accepted: 01/16/2024] [Indexed: 03/19/2024]
Abstract
Current treatments against organophosphate poisoning (OPP) do not directly address effects mediated by the overstimulation of nicotinic acetylcholine receptors (nAChR). Non-oxime bispyridinium compounds (BPC) promote acetylcholine esterase-independent recovery of organophosphate-induced paralysis. Here, we test the hypothesis that they act by positive modulatory action on nAChRs. Using two-electrode voltage clamp analysis in combination with mutagenesis and molecular docking analysis, the potency and molecular mode of action of a series of nine BPCs was investigated on human α7 and muscle-type nAChRs expressed in Xenopus laevis oocytes. The investigated BPCs inhibited α7 and/or muscle-type nAChRs with IC50 values in the high nanomolar to high micromolar range. Further analysis of the most potent analogues revealed a noncompetitive, voltage-dependent inhibition. Co-application with the α7-selective positive allosteric modulator PNU120596 and generation of α7/5HT3 receptor chimeras excluded direct interaction with the PNU120596 binding site and binding to the extracellular domain of the α7 nAChR, suggesting that they act as open channel blockers (OCBs). Molecular docking supported by mutagenesis localized the BPC binding area in the outer channel vestibule between the extracellular and transmembrane domains. Analysis of BPC action on other cation-selective channels suggests a rather nonspecific inhibition of pentameric cation channels. BPCs have been shown to ameliorate organophosphate-induced paralysis in vitro and in vivo. Our data support molecular action as OCBs at α7 and muscle-type nAChRs and suggest that their positive physiological effects are more complex than anticipated and require further investigation.
Collapse
Affiliation(s)
- Yves Haufe
- Walther
Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, 80336 Munich, Germany
| | - Dominik Loser
- NMI
Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany
| | - Timm Danker
- NMI
Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany
| | - Annette Nicke
- Walther
Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, 80336 Munich, Germany
| |
Collapse
|
2
|
Papke RL, Quadri M, Gulsevin A. Silent agonists for α7 nicotinic acetylcholine receptors. Pharmacol Res 2023; 190:106736. [PMID: 36940890 DOI: 10.1016/j.phrs.2023.106736] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Revised: 03/07/2023] [Accepted: 03/14/2023] [Indexed: 03/23/2023]
Abstract
We discuss models for the activation and desensitization of α7 nicotinic acetylcholine receptors (nAChRs) and the effects of efficacious type II positive allosteric modulators (PAMs) that destabilize α7 desensitized states. Type II PAMs such as PNU-120596 can be used to distinguish inactive compounds from silent agonists, compounds that produce little or no channel activation but stabilize the non-conducting conformations associated with desensitization. We discuss the effects of α7 nAChRs in cells of the immune system and their roles in modulating inflammation and pain through what has come to be known as the cholinergic anti-inflammatory system (CAS). Cells controlling CAS do not generate ion channel currents but rather respond to α7 drugs by modulating intracellular signaling pathways analogous to the effects of metabotropic receptors. Metabotropic signaling by α7 receptors appears to be mediated by receptors in nonconducting conformations and can be accomplished by silent agonists. We discuss electrophysiological structure-activity relationships for α7 silent agonists and their use in cell-based and in vivo assays for CAS regulation. We discuss the strongly desensitizing partial agonist GTS-21 and its effectiveness in modulation of CAS. We also review the properties of the silent agonist NS6740, which is remarkably effective at maintaining α7 receptors in PAM-sensitive desensitized states. Most silent agonists bind to sites overlapping those for orthosteric agonists, but some appear to bind to allosteric sites. Finally, we discuss α9⁎ nAChRs and their potential role in CAS, and ligands that will be useful in defining and distinguishing the specific roles of α7 and α9 in CAS.
Collapse
Affiliation(s)
- Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (RLP); Olon S.p.A., Strada Rivoltana, Km 6/7 - 20053 Rodano (MI) - ITALY (MQ); Department of Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA, 37212 (AG).
| | - Marta Quadri
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (RLP); Olon S.p.A., Strada Rivoltana, Km 6/7 - 20053 Rodano (MI) - ITALY (MQ); Department of Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA, 37212 (AG)
| | - Alican Gulsevin
- Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267 Gainesville, FL 32610 USA (RLP); Olon S.p.A., Strada Rivoltana, Km 6/7 - 20053 Rodano (MI) - ITALY (MQ); Department of Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA, 37212 (AG)
| |
Collapse
|
3
|
Borroni V, Barrantes FJ. Homomeric and Heteromeric α7 Nicotinic Acetylcholine Receptors in Health and Some Central Nervous System Diseases. MEMBRANES 2021; 11:membranes11090664. [PMID: 34564481 PMCID: PMC8465519 DOI: 10.3390/membranes11090664] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 08/24/2021] [Accepted: 08/24/2021] [Indexed: 11/22/2022]
Abstract
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels involved in the modulation of essential brain functions such as memory, learning, and attention. Homomeric α7 nAChR, formed exclusively by five identical α7 subunits, is involved in rapid synaptic transmission, whereas the heteromeric oligomers composed of α7 in combination with β subunits display metabotropic properties and operate in slower time frames. At the cellular level, the activation of nAChRs allows the entry of Na+ and Ca2+; the two cations depolarize the membrane and trigger diverse cellular signals, depending on the type of nAChR pentamer and neurons involved, the location of the intervening cells, and the networks of which these neuronal cells form part. These features make the α7 nAChR a central player in neurotransmission, metabolically associated Ca2+-mediated signaling, and modulation of diverse fundamental processes operated by other neurotransmitters in the brain. Due to its ubiquitous distribution and the multiple functions it displays in the brain, the α7 nAChR is associated with a variety of neurological and neuropsychiatric disorders whose exact etiopathogenic mechanisms are still elusive.
Collapse
Affiliation(s)
- Virginia Borroni
- Instituto de Tecnología en Polímeros y Nanotecnología (ITPN-UBA-CONICET), Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires C1127AAR, Argentina;
| | - Francisco J. Barrantes
- Laboratory of Molecular Neurobiology, Institute for Biomedical Research, UCA–CONICET, Faculty of Medical Sciences, Catholic University of Argentina, Av. Alicia Moreau de Justo 1600, Buenos Aires C1107AAZ, Argentina
- Correspondence:
| |
Collapse
|
4
|
Abstract
The α7-type nicotinic acetylcholine receptor is one of the most unique and interesting of all the members of the cys-loop superfamily of ligand-gated ion channels. Since it was first identified initially as a binding site for α-bungarotoxin in mammalian brain and later as a functional homomeric receptor with relatively high calcium permeability, it has been pursued as a potential therapeutic target for numerous indications, from Alzheimer disease to asthma. In this review, we discuss the history and state of the art for targeting α7 receptors, beginning with subtype-selective agonists and the basic pharmacophore for the selective activation of α7 receptors. A key feature of α7 receptors is their rapid desensitization by standard "orthosteric" agonist, and we discuss insights into the conformational landscape of α7 receptors that has been gained by the development of ligands binding to allosteric sites. Some of these sites are targeted by positive allosteric modulators that have a wide range of effects on the activation profile of the receptors. Other sites are targeted by direct allosteric agonist or antagonists. We include a perspective on the potential importance of α7 receptors for metabotropic as well as ionotropic signaling. We outline the challenges that exist for future development of drugs to target this important receptor and approaches that may be considered to address those challenges. SIGNIFICANCE STATEMENT: The α7-type nicotinic acetylcholine receptor (nAChR) is acknowledged as a potentially important therapeutic target with functional properties associated with both ionotropic and metabotropic signaling. The functional properties of α7 nAChR can be regulated in diverse ways with the variety of orthosteric and allosteric ligands described in this review.
Collapse
Affiliation(s)
- Roger L Papke
- Departments of Pharmacology and Therapeutics (R.L.P) and Chemistry (N.A.H.), University of Florida, Gainesville, FL
| | - Nicole A Horenstein
- Departments of Pharmacology and Therapeutics (R.L.P) and Chemistry (N.A.H.), University of Florida, Gainesville, FL
| |
Collapse
|
5
|
Pismataro MC, Horenstein NA, Stokes C, Dallanoce C, Thakur GA, Papke RL. Stable desensitization of α 7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. Eur J Pharmacol 2021; 905:174179. [PMID: 34004208 DOI: 10.1016/j.ejphar.2021.174179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 05/05/2021] [Accepted: 05/12/2021] [Indexed: 01/09/2023]
Abstract
NS6740 is an α7 nicotinic acetylcholine receptor-selective partial agonist with low efficacy for channel activation, capable of promoting the stable conversion of the receptors to nonconducting (desensitized) states that can be reactivated with the application of positive allosteric modulators (PAMs). In spite of its low efficacy for channel activation, NS6740 is an effective activator of the cholinergic anti-inflammatory pathway. We observed that the concentration-response relationships for channel activation, both when applied alone and when co-applied with the PAM PNU-120596 are inverted-U shaped with inhibitory/desensitizing activities dominant at high concentrations. We evaluated the potential importance of recently identified binding sites for allosteric activators and tested the hypotheses that the stable desensitization produced by NS6740 may be due to binding to these sites. Our experiments were guided by molecular modeling of NS6740 binding to both the allosteric and orthosteric activation sites on the receptor. Our results indicate that with α7C190A mutants, which have compromised orthosteric activation sites, NS6740 may work at the allosteric activation sites to promote transient PAM-dependent currents but not the stable desensitization seen with wild-type α7 receptors. Modeling NS6740 in the orthosteric binding sites identified S36 as an important residue for NS6740 binding and predicted that an S36V mutation would limit NS6740 activity. The efficacy of NS6740 for α7S36V receptors was reduced to zero, and applications of the compound to α7S36V receptors failed to induce the desensitization observed with wild-type receptors. The results indicate that the unique properties of NS6740 are due primarily to binding at the sites for orthosteric agonists.
Collapse
Affiliation(s)
- Maria Chiara Pismataro
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy; Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL, 32611-7200, USA
| | - Nicole A Horenstein
- Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, FL, 32611-7200, USA
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA
| | - Clelia Dallanoce
- Department of Pharmaceutical Sciences, Medicinal Chemistry Section "Pietro Pratesi", University of Milan, Via L. Mangiagalli 25, 20133, Milan, Italy.
| | - Ganesh A Thakur
- Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, 02115, USA
| | - Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA
| |
Collapse
|
6
|
Miller DR, Khoshbouei H, Garai S, Cantwell LN, Stokes C, Thakur G, Papke RL. Allosterically Potentiated α7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium. Mol Pharmacol 2020; 98:695-709. [PMID: 33020143 DOI: 10.1124/molpharm.120.000012] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Accepted: 09/10/2020] [Indexed: 11/22/2022] Open
Abstract
The currents of α7 nicotinic acetylcholine receptors activated by acetylcholine (ACh) are brief. The channel has high permeability to calcium relative to monovalent cations and shows inward rectification. It has been previously noted that in the presence of positive allosteric modulators (PAMs), currents through the channels of α7 receptors differ from normal α7 currents both in sensitivity to specific channel blockers and their current-voltage (I-V) relationships, no longer showing inward rectification. Linear I-V functions are often associated with channels lacking calcium permeability, so we measured the I-V functions of α7 receptors activated by ACh when PAMs were bound to the allosteric binding site in the transmembrane domain. Currents were recorded in chloride-free Ringer's solution with low or high concentrations of extracellular calcium to determine the magnitude of the reversal potential shift in the two conditions as well as the I-V relationships. ACh-evoked currents potentiated by the allosteric agonist-PAMs (ago-PAMs) (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (GAT107) and 3-(3,4-difluorophenyl)-N-(1-(6-(4-(pyridin-2-yl)piperazin-1-yl)pyrazin-2-yl)ethyl)propenamide (B-973B) showed reduced inward rectification and calcium-dependent reversal potential shifts decreased by 80%, and 50%, respectively, compared with currents activated by ACh alone, indicative of reduced calcium permeability. Currents potentiated by 3a,4,5,9b-tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide were also linear and showed no calcium-dependent reversal potential shifts. The ago-PAMs GAT-107 and B-973B stimulated increases in intracellular calcium in stably transfected HEK293 cells. However, these calcium signals were delayed relative to channel activation produced by these agents and were insensitive to the channel blocker mecamylamine. Our results indicate that, although allosterically activated α7 nicotinic ACh receptor may affect intracellular calcium levels, such effects are not likely due to large channel-dependent calcium influx. SIGNIFICANCE STATEMENT: Positive allosteric modulators (PAMs) of α7 nicotinic acetylcholine receptor can increase channel activation by two or more orders of magnitude, raising the concern that, due to the relatively high calcium permeability of α7 receptors activated by acetylcholine alone, such efficacious PAMs may have cytotoxic side effects. We show that PAMs alter the ion conduction pathway and, in general, reduce the calcium permeability of the channels. This supports the hypothesis that α7 effects on intracellular calcium may be independent of channel-mediated calcium influx.
Collapse
Affiliation(s)
- Douglas R Miller
- Departments of Neuroscience (D.R.M., H.K.) and Pharmacology and Therapeutics (C.S., R.L.P.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., L.N.C., G.T.)
| | - Habibeh Khoshbouei
- Departments of Neuroscience (D.R.M., H.K.) and Pharmacology and Therapeutics (C.S., R.L.P.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., L.N.C., G.T.)
| | - Sumanta Garai
- Departments of Neuroscience (D.R.M., H.K.) and Pharmacology and Therapeutics (C.S., R.L.P.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., L.N.C., G.T.)
| | - Lucas N Cantwell
- Departments of Neuroscience (D.R.M., H.K.) and Pharmacology and Therapeutics (C.S., R.L.P.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., L.N.C., G.T.)
| | - Clare Stokes
- Departments of Neuroscience (D.R.M., H.K.) and Pharmacology and Therapeutics (C.S., R.L.P.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., L.N.C., G.T.)
| | - Ganesh Thakur
- Departments of Neuroscience (D.R.M., H.K.) and Pharmacology and Therapeutics (C.S., R.L.P.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., L.N.C., G.T.)
| | - Roger L Papke
- Departments of Neuroscience (D.R.M., H.K.) and Pharmacology and Therapeutics (C.S., R.L.P.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., L.N.C., G.T.)
| |
Collapse
|
7
|
Papke RL, Lindstrom JM. Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling. Neuropharmacology 2020; 168:108021. [PMID: 32146229 PMCID: PMC7610230 DOI: 10.1016/j.neuropharm.2020.108021] [Citation(s) in RCA: 66] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Revised: 02/05/2020] [Accepted: 02/25/2020] [Indexed: 12/28/2022]
Abstract
Postsynaptic nAChRs in the peripheral nervous system are critical for neuromuscular and autonomic neurotransmission. Pre- and peri-synaptic nAChRs in the brain modulate neurotransmission and are responsible for the addictive effects of nicotine. Subtypes of nAChRs in lymphocytes and non-synaptic locations may modulate inflammation and other cellular functions. All AChRs that function as ligand-gated ion channels are formed from five homologous subunits organized to form a central cation channel whose opening is regulated by ACh bound at extracellular subunit interfaces. nAChR subtype subunit composition can range from α7 homomers to α4β2α6β2β3 heteromers. Subtypes differ in affinities for ACh and other agonists like nicotine and in efficiencies with which their channels are opened and desensitized. Subtypes also differ in affinities for antagonists and for positive and negative allosteric modulators. Some agonists are "silent" with respect to channel opening, and AChRs may be able to signal metabotropic pathways by releasing G-proteins independent of channel opening. Electrophysiological studies that can resolve single-channel openings and molecular genetic approaches have allowed characterization of the structures of ligand binding sites, the cation channel, and the linkages between them, as well as the organization of AChR subunits and their contributions to function. Crystallography and cryo-electron-microscopy are providing increasing insights into the structures and functions of AChRs. However, much remains to be learned about both AChR structure and function, the in vivo functional roles of some AChR subtypes, and the development of better pharmacological tools directed at AChRs to treat addiction, pain, inflammation, and other medically important issues. This article is part of the special issue on 'Contemporary Advances in Nicotine Neuropharmacology'.
Collapse
Affiliation(s)
- Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, P.O. Box 100267, Gainesville, FL, 32610-0267, USA.
| | - Jon M Lindstrom
- Department of Neuroscience, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
8
|
Quadri M, Garai S, Thakur GA, Stokes C, Gulsevin A, Horenstein NA, Papke RL. Macroscopic and Microscopic Activation of α7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. Mol Pharmacol 2019; 95:43-61. [PMID: 30348894 PMCID: PMC6277926 DOI: 10.1124/mol.118.113340] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 10/18/2018] [Indexed: 01/25/2023] Open
Abstract
B-973 is an efficacious type II positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptors that, like 4BP-TQS and its active isomer GAT107, can produce direct allosteric activation in addition to potentiation of orthosteric agonist activity, which identifies it as an allosteric activating (ago)-PAM. We compared the properties of B-973B, the active enantiomer of B-973, with those of GAT107 regarding the separation of allosteric potentiation and activation. Both ago-PAMs can strongly activate mutants of α7 that are insensitive to standard orthosteric agonists like acetylcholine. Likewise, the activity of both ago-PAMs is largely eliminated by the M254L mutation in the putative transmembrane PAM-binding site. Allosteric activation by B-973B appeared more protracted than that produced by GAT107, and B-973B responses were relatively insensitive to the noncompetitive antagonist mecamylamine compared with GAT107 responses. Similar differences are also seen in the single-channel currents. The two agents generate unique profiles of full-conductance and subconductance states, with B-973B producing protracted bursts, even in the presence of mecamylamine. Modeling and docking studies suggest that the molecular basis for these effects depends on specific interactions in both the extracellular and transmembrane domains of the receptor.
Collapse
Affiliation(s)
- Marta Quadri
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Sumanta Garai
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Ganesh A Thakur
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Clare Stokes
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Alican Gulsevin
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Nicole A Horenstein
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| | - Roger L Papke
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., A.G., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.)
| |
Collapse
|
9
|
Quadri M, Bagdas D, Toma W, Stokes C, Horenstein NA, Damaj MI, Papke RL. The Antinociceptive and Anti-Inflammatory Properties of the α7 nAChR Weak Partial Agonist p-CF 3 N, N-diethyl- N'-phenylpiperazine. J Pharmacol Exp Ther 2018; 367:203-214. [PMID: 30111636 DOI: 10.1124/jpet.118.249904] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 08/13/2018] [Indexed: 12/13/2022] Open
Abstract
Chronic pain and inflammatory diseases can be regulated by complex mechanisms involving α7 nicotinic acetylcholine receptors (nAChRs), making this subtype a promising drug target for anti-inflammatory therapies. Recent evidence suggests that suchtreatment of inflammatory pain may rely on metabotropic-like rather than ionotropic activation of the α7 receptor subtype in non-neuronal cells. We previously identified para-trifluoromethyl (p-CF3) N,N-diethyl-N'-phenylpiperazinium (diEPP) iodide to be among the compounds classified as silent agonists, which are very weak α7 partial agonists that are able to induce positive allosteric modulator (PAM)-sensitive desensitization. Such drugs have been shown to selectively promote α7 ionotropic-independent functions. Therefore, we here further investigated the electrophysiological profile of p-CF3 diEPP and its in vivo antinociceptive activity using Xenopus oocytes expressing α7, α4β2, or α3β4 nAChRs. The evoked currents confirmed p-CF3 diEPP to be α7-selective with a maximal agonism 5% that of acetylcholine (ACh). Coapplication of p-CF3 diEPP with the type II PAM 4-naphthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide (TQS) produced desensitization that could be converted to PAM-potentiated currents, which at a negative holding potential were up to 13-fold greater than ACh controls. Voltage-dependence experiments indicated that channel block may limit both control ACh and TQS-potentiated responses. Although no p-CF3 diEPP agonist activity was detected for the heteromeric nAChRs, it was a noncompetitive antagonist of these receptors. The compound displayed remarkable antihyperalgesic and antiedema effects in in vivo assays. The antinociceptive activity was dose and time dependent. The anti-inflammatory components were sensitive to the α7-selective antagonist methyllycaconitine, which supports the idea that these effects are mediated by the α7 nAChR.
Collapse
Affiliation(s)
- Marta Quadri
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Deniz Bagdas
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Wisam Toma
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Clare Stokes
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Nicole A Horenstein
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - M Imad Damaj
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| | - Roger L Papke
- Departments of Pharmacology and Therapeutics (M.Q., C.S., R.L.P.) and Chemistry (M.Q., N.A.H.), University of Florida, Gainesville, Florida; and Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia (D.B., W.T., M.I.D.)
| |
Collapse
|
10
|
Nanclares C, Gameiro-Ros I, Méndez-López I, Martínez-Ramírez C, Padín-Nogueira JF, Colmena I, Baraibar AM, Gandía L, García AG. Dual Antidepressant Duloxetine Blocks Nicotinic Receptor Currents, Calcium Signals and Exocytosis in Chromaffin Cells Stimulated with Acetylcholine. J Pharmacol Exp Ther 2018; 367:28-39. [PMID: 30006476 DOI: 10.1124/jpet.118.250969] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 07/12/2018] [Indexed: 01/09/2023] Open
Abstract
The inhibition of nicotinic acetylcholine receptors (nAChRs) has been proposed as a potential strategy to develop new antidepressant drugs. This is based on the observation that antidepressants that selectively block noradrenaline (NA) or serotonin (5-HT) reuptake also inhibit nAChRs. Dual antidepressants blocking both NA and 5-HT reuptake were proposed to shorten the delay in exerting their clinical effects; whether duloxetine, a prototype of dual antidepressants, also blocks nAChRs is unknown. Here we explored this question in bovine chromaffin cells (BCCs) that express native α3, α5, and α7 nAChRs and in cell lines expressing human α7, α3β4, or α4β2 nAChRs. We have found that duloxetine fully blocked the acetylcholine (ACh)-elicited nicotinic currents in BCCs with an IC50 of 0.86 µM. Such blockade seemed to be noncompetitive, voltage dependent, and partially use dependent. The ACh-elicited membrane depolarization, the elevation of cytosolic calcium ([Ca2+]c), and catecholamine release in BCCs were also blocked by duloxetine. This blockade developed slowly, and the recovery of secretion was also slow and gradual. Duloxetine did not affect Na+ or Ca2+ channel currents neither the high-K+-elicited [Ca2+]c transients and secretion. Of interest was that in cell lines expressing human α7, α3β4, and α4β2 nAChRs, duloxetine blocked nicotinic currents with IC50 values of 0.1, 0.56, and 0.85 µM, respectively. Thus, in blocking α7 receptors, which are abundantly expressed in the brain, duloxetine exhibited approximately 10-fold to 100- fold higher potency with respect to reported IC50 values for various antidepressant drugs. This may contribute to the antidepressant effect of duloxetine.
Collapse
Affiliation(s)
- Carmen Nanclares
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - Isabel Gameiro-Ros
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - Iago Méndez-López
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - Carmen Martínez-Ramírez
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - J Fernando Padín-Nogueira
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - Inés Colmena
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - Andrés M Baraibar
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - Luis Gandía
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| | - Antonio G García
- Instituto Teófilo Hernando and Departamento de Farmacología, Facultad de Medicina (C.N., I.G.-R., I.M.-L., C.M.-R., J.F.P.-N., I.C., A.M.B., L.G., A.G.G.) and Instituto de Investigación Sanitaria, Hospital Universitario de La Princesa (A.G.G.), Universidad Autónoma de Madrid, Madrid, Spain; and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla La Mancha (UCLM), Ciudad Real, Spain (J.F.P.-N.)
| |
Collapse
|
11
|
Bagdas D, Gurun MS, Flood P, Papke RL, Damaj MI. New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs. Curr Neuropharmacol 2018; 16:415-425. [PMID: 28820052 PMCID: PMC6018191 DOI: 10.2174/1570159x15666170818102108] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 06/20/2017] [Accepted: 08/16/2017] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Nicotine and nicotinic acetylcholine receptors (nAChRs) have been explored for the past three decades as targets for pain control. The aim of this review is to introduce readers particularly to α7 nAChRs in a perspective of pain and its modulation. METHODS Developments for α7 nAChR modulators and recent animal studies related to pain are reviewed. RESULTS Accumulating evidences suggest that selective ligands for α7 nAChRs hold promise in the treatment of chronic pain conditions as they lack many of side effects associated with other nicotinic receptor types. CONCLUSION This review provides the reader recent insights on α7 nAChRs from structure and function to the latest findings on the pharmacology and therapeutic targeting of these receptors for the treatment of pain and inflammation.
Collapse
Affiliation(s)
- Deniz Bagdas
- Address correspondence to this author at the Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298-0613; Tel/Fax: +1-804-828-9256; E-mail:
| | | | | | | | | |
Collapse
|
12
|
Scheffel C, Niessen KV, Rappenglück S, Wanner KT, Thiermann H, Worek F, Seeger T. Counteracting desensitization of human α7-nicotinic acetylcholine receptors with bispyridinium compounds as an approach against organophosphorus poisoning. Toxicol Lett 2017; 293:149-156. [PMID: 29248576 DOI: 10.1016/j.toxlet.2017.12.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Revised: 12/07/2017] [Accepted: 12/09/2017] [Indexed: 01/30/2023]
Abstract
Irreversible inhibition of acetylcholinesterase (AChE) resulting in accumulation of acetylcholine and overstimulation of muscarinic and nicotinic receptors accounts for the acute toxicity of organophosphorus compounds (OP). Accordingly, the mainstay pharmacotherapy against poisoning by OP comprises the competitive muscarinic acetylcholine receptor antagonist atropine to treat muscarinic effects and, in addition, oximes to reactivate inhibited AChE. A therapeutic gap still remains in the treatment of desensitized nicotinic acetylcholine receptors following OP exposure. Hereby, nicotinic effects result in paralysis of the central and peripheral respiratory system if untreated. Thus, these receptors pose an essential target for therapeutic indication to address these life-threatening nicotinic symptoms of the cholinergic crisis. Identification of ligands regulating dynamic transitions between functional states by binding to modulatory sites appears to be a promising strategy for therapeutic intervention. In this patch clamp study, the ability of differently substituted bispyridinium non-oximes to "resensitize" i.e. to recover the activity of desensitized human homomeric α7-type nAChRs stably transfected in CHO cells was investigated and compared to the already described α7-specific positive allosteric modulator PNU-120596. The structures of these bispyridinium analogues were based on the lead structure of the tert-butyl-substituted bispyridinium propane MB327, which has been shown to have a positive therapeutic effect due to a non-competitive antagonistic action at muscle-type nAChRs in vivo and has been found to have a positive allosteric activity at neuronal receptors in vitro. Prior to test compounds, desensitization of hα7-nAChRs was verified by applying an excess of nicotine revealing activation at low, and desensitization at high concentrations. Thereby, desensitization could be reduced by modulation with PNU-120596. Desensitization was further verified by dose-response profiles of agonists, carbamoylcholine and epibatidine in the absence and presence of PNU-120596. Although less pronounced than PNU-120596 and the lead structure MB327, bispyridinium compounds, particularly those substituted at position 3 and 4, resensitized the nicotine desensitized hα7-nAChRs in a concentration-dependent manner and prolonged the mean channel open time. In summary, identification of more potent compounds able to restore nAChR function in OP intoxication is needed for development of a putative efficient antidote.
Collapse
Affiliation(s)
- Corinna Scheffel
- Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany; Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, Germany.
| | - Karin V Niessen
- Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
| | | | - Klaus T Wanner
- Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
| | - Horst Thiermann
- Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
| | - Franz Worek
- Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
| | - Thomas Seeger
- Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany
| |
Collapse
|
13
|
Shelukhina I, Spirova E, Kudryavtsev D, Ojomoko L, Werner M, Methfessel C, Hollmann M, Tsetlin V. Calcium imaging with genetically encoded sensor Case12: Facile analysis of α7/α9 nAChR mutants. PLoS One 2017; 12:e0181936. [PMID: 28797116 PMCID: PMC5552293 DOI: 10.1371/journal.pone.0181936] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 07/10/2017] [Indexed: 11/17/2022] Open
Abstract
Elucidation of the structural basis of pharmacological differences for highly homologous α7 and α9 nicotinic acetylcholine receptors (nAChRs) may shed light on their involvement in different physiological functions and diseases. Combination of site-directed mutagenesis and electrophysiology is a powerful tool to pinpoint the key amino-acid residues in the receptor ligand-binding site, but for α7 and α9 nAChRs it is complicated by their poor expression and fast desensitization. Here, we probed the ligand-binding properties of α7/α9 nAChR mutants by a proposed simple and fast calcium imaging method. The method is based on transient co-expression of α7/α9 nAChR mutants in neuroblastoma cells together with Ric-3 or NACHO chaperones and Case12 fluorescent calcium ion sensor followed by analysis of their pharmacology using a fluorescence microscope or a fluorometric imaging plate reader (FLIPR) with a GFP filter set. The results obtained were confirmed by electrophysiology and by calcium imaging with the conventional calcium indicator Fluo-4. The affinities for acetylcholine and epibatidine were determined for human and rat α7 nAChRs, and for their mutants with homologous residues of α9 nAChR incorporated at positions 117-119, 184, 185, 187, and 189, which are anticipated to be involved in ligand binding. The strongest decrease in the affinity was observed for mutations at positions 187 and 119. The L119D mutation of α7 nAChR, showing a larger effect for epibatidine than for acetylcholine, may implicate this position in pharmacological differences between α7 and α9 nAChRs.
Collapse
Affiliation(s)
- Irina Shelukhina
- Department of Molecular Basis of Neurosignalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Ekaterina Spirova
- Department of Molecular Basis of Neurosignalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Denis Kudryavtsev
- Department of Molecular Basis of Neurosignalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Lucy Ojomoko
- Department of Molecular Basis of Neurosignalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Markus Werner
- Department of Biochemistry I, Ruhr University Bochum, Bochum, Germany
| | | | - Michael Hollmann
- Department of Biochemistry I, Ruhr University Bochum, Bochum, Germany
| | - Victor Tsetlin
- Department of Molecular Basis of Neurosignalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
14
|
King JR, Gillevet TC, Kabbani N. A G protein-coupled α7 nicotinic receptor regulates signaling and TNF-α release in microglia. FEBS Open Bio 2017; 7:1350-1361. [PMID: 28904864 PMCID: PMC5586346 DOI: 10.1002/2211-5463.12270] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 07/14/2017] [Indexed: 11/21/2022] Open
Abstract
Acetylcholine activation of α7 nicotinic acetylcholine receptors (α7 nAChRs) in microglia attenuates neuroinflammation and regulates TNF‐α release. We used lipopolysaccharide to model inflammation in the microglial cell line EOC20 and examined signaling by the α7 nAChR. Co‐immunoprecipitation experiments confirm that α7 nAChRs bind heterotrimeric G proteins in EOC20 cells. Interaction with Gαi mediates α7 nAChR signaling via enhanced intracellular calcium release and a decrease in cAMP, p38 phosphorylation, and TNF‐α release. These α7 nAChR effects were blocked by the inhibition of Gαi signaling via pertussis toxin, PLC activity with U73122, and α7 nAChR channel activity with the selective antagonist α‐bungarotoxin. Moreover, α7 nAChR signaling in EOC20 cells was significantly diminished by the expression of a dominant‐negative α7 nAChR, α7345‐8A, shown to be impaired in G protein binding. These findings indicate an essential role for G protein coupling in α7 nAChR function in microglia leading to the regulation of inflammation in the nervous system.
Collapse
Affiliation(s)
- Justin R King
- Interdisciplinary Program in Neuroscience Krasnow Institute for Advanced Study George Mason University Fairfax VA USA
| | - Trudy C Gillevet
- Interdisciplinary Program in Neuroscience Krasnow Institute for Advanced Study George Mason University Fairfax VA USA
| | - Nadine Kabbani
- School of Systems Biology Krasnow Institute for Advanced Study George Mason University Fairfax VA USA
| |
Collapse
|
15
|
Papke RL, Stokes C, Damaj MI, Thakur GA, Manther K, Treinin M, Bagdas D, Kulkarni AR, Horenstein NA. Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states. Br J Pharmacol 2017; 175:1838-1854. [PMID: 28477386 DOI: 10.1111/bph.13851] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Revised: 04/25/2017] [Accepted: 05/03/2017] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND AND PURPOSE GAT107 ((3aR,4S,9bS)-4-(4-bromo-phenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta-[c]quinoline-8-sulfonamide) is a positive allosteric modulator (PAM) and agonist of α7 nicotinic acetylcholine receptors (nAChRs)that can cause a prolonged period of primed potentiation of acetylcholine responses after drug washout. NS6740 is a silent agonist of α7 nAChRs that has little or no efficacy for activating the ion channel but induces stable desensitization states, some of which can be converted into channel-active states by PAMs. Although GAT107 and NS6740 appear to stably induce different non-conducting states, both agents are effective treatment for inflammation and inflammatory pain models. We sought to better understand how both of these drugs that have opposite effects on channel activation could regulate signal transduction. EXPERIMENTAL APPROACH Voltage-clamp experiments were conducted with α7 nAChRs expressed in Xenopus oocytes. KEY RESULTS Long-lived sensitivity to a PAM or to an agonist was produced by NS6740 or GAT107 respectively. With sequential applications, these two drugs induced varying levels of persistent activation, which is a unique condition for a receptor that is known for rapid desensitization. The non-conducting states induced by NS6740 or GAT107 differ in their sensitivity to an α7 nAChR-selective antagonist and in how effectively they promote current. CONCLUSIONS & IMPLICATIONS Our data suggest that the persistent currents represent a dynamic interconversion between different stable desensitized states and the PAM-inducible conducting states. However, the similarity of NS6740 and GAT107 effects on inflammation and pain suggests that the different stable non-conducting states have common activity on signal transduction. LINKED ARTICLES This article is part of a themed section on Nicotinic Acetylcholine Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.11/issuetoc.
Collapse
Affiliation(s)
- Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA
| | - Clare Stokes
- Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA
| | - M Imad Damaj
- Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA
| | - Ganesh A Thakur
- Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA
| | - Khan Manther
- Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA
| | - Millet Treinin
- Department of Medical Neurobiology, Hadassah Medical School, Hebrew University, Jerusalem, Israel
| | - Deniz Bagdas
- Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.,Experimental Animals Breeding and Research Center, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - Abhijit R Kulkarni
- Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA
| | | |
Collapse
|
16
|
Mueller A, Starobova H, Inserra MC, Jin AH, Deuis JR, Dutertre S, Lewis RJ, Alewood PF, Daly NL, Vetter I. α-Conotoxin MrIC is a biased agonist at α7 nicotinic acetylcholine receptors. Biochem Pharmacol 2015; 94:155-63. [PMID: 25646788 DOI: 10.1016/j.bcp.2015.01.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Revised: 01/20/2015] [Accepted: 01/20/2015] [Indexed: 12/23/2022]
Abstract
MrIC is a recently described selective agonist of endogenously expressed α7 nAChR. In this study, we further characterize the pharmacological activity of MrIC using Ca(2+) imaging approaches in SH-SY5Y cells endogenously expressing α7 nAChR and demonstrate that MrIC exclusively activates α7 nAChR modulated by type II positive allosteric modulators, including PNU120596. MrIC was a full agonist at PNU120596-modulated α7 nAChR compared with choline, albeit with slower kinetics, but failed to elicit a Ca(2+) response in the absence of PNU120596. Interestingly, the NMR structure of MrIC showed a typical 4/7 α-conotoxin fold, indicating that its unusual pharmacological activity is likely sequence-dependent. Overall, our results suggest that MrIC acts as a biased agonist that can only activate α7 nAChR modified by type II positive allosteric modulators, and thus represents a valuable tool to probe the pharmacological properties of this important ion channel.
Collapse
Affiliation(s)
- Alexander Mueller
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Hana Starobova
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Marco C Inserra
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Ai-Hua Jin
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Jennifer R Deuis
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Sébastien Dutertre
- Institut des Biomolécules Max Mousseron, UMR 5247, Université Montpellier 2-CNRS, Place Eugène Bataillon, Montpellier Cedex 5 34095, France
| | - Richard J Lewis
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Paul F Alewood
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Norelle L Daly
- Centre for Biodiscovery and Molecular Development of Therapeutics, AITHM, James Cook University, Queensland 4878, Australia
| | - Irina Vetter
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland 4072, Australia; School of Pharmacy, The University of Queensland, Woolloongabba, Queensland 4102, Australia.
| |
Collapse
|
17
|
van Maanen MA, Papke RL, Koopman FA, Koepke J, Bevaart L, Clark R, Lamppu D, Elbaum D, LaRosa GJ, Tak PP, Vervoordeldonk MJ. Two novel α7 nicotinic acetylcholine receptor ligands: in vitro properties and their efficacy in collagen-induced arthritis in mice. PLoS One 2015; 10:e0116227. [PMID: 25617631 PMCID: PMC4305287 DOI: 10.1371/journal.pone.0116227] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Accepted: 12/04/2014] [Indexed: 11/28/2022] Open
Abstract
INTRODUCTION The cholinergic anti-inflammatory pathway can downregulate inflammation via the release of acetylcholine (ACh) by the vagus nerve. This neurotransmitter binds to the α7 subunit of nicotinic acetylcholine receptors (α7nAChR), expressed on macrophages and other immune cells. We tested the pharmacological and functional profile of two novel compounds, PMP-311 and PMP-072 and investigated their role in modulating collagen-induced arthritis (CIA) in mice. METHODS Both compounds were characterized with binding, electrophysiological, and pharmacokinetic studies. For in vivo efficacy studies in the CIA model the compounds were administered daily by oral gavage from day 20 till sacrifice at day 34. Disease progression was monitored by visual clinical scoring and measurement of paw swelling. Inflammation and joint destruction were examined by histology and radiology. RESULTS Treatment with PMP-311 was effective in preventing disease onset, reducing clinical signs of arthritis, and reducing synovial inflammation and bone destruction. PMP-072 also showed a trend in arthritis reduction at all concentrations tested. The data showed that while both compounds bind to α7nAChR with high affinity, PMP-311 acts like a classical agonist of ion channel activity, and PMP-072 can actually act as an ion channel antagonist. Moreover, PMP-072 was clearly distinct from typical competitive antagonists, since it was able to act as a silent agonist. It synergizes with the allosteric modulator PNU-120596, and subsequently activates desensitized α7nAChR. However, PMP-072 was less efficacious than PMP-311 at both channel activation and desensitization, suggesting that both conducting and non-conducting states maybe of importance in driving an anti-inflammatory response. Finally, we found that the anti-arthritic effect can be observed despite limited penetration of the central nervous system. CONCLUSIONS These data provide direct evidence that the α7nAChR in immune cells does not require typical ion channel activation to exert its antiinflammatory effects.
Collapse
Affiliation(s)
- Marjolein A. van Maanen
- Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
| | - Roger L. Papke
- Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida, United States of America
| | - Frieda A. Koopman
- Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
| | - Jessica Koepke
- Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
- Arthrogen BV, Amsterdam, The Netherlands
| | - Lisette Bevaart
- Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
- Arthrogen BV, Amsterdam, The Netherlands
| | - Roger Clark
- Cornerstone Therapeutics, Inc., Cary, North Carolina, United States of America
| | - Diana Lamppu
- Cornerstone Therapeutics, Inc., Cary, North Carolina, United States of America
| | - Daniel Elbaum
- DEC Associates, LLC, Newton, Massachusetts, United States of America
| | - Gregory J. LaRosa
- Cornerstone Therapeutics, Inc., Cary, North Carolina, United States of America
| | - Paul P. Tak
- Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
| | - Margriet J. Vervoordeldonk
- Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
- Arthrogen BV, Amsterdam, The Netherlands
- * E-mail:
| |
Collapse
|
18
|
|
19
|
Papke RL. Merging old and new perspectives on nicotinic acetylcholine receptors. Biochem Pharmacol 2014; 89:1-11. [PMID: 24486571 PMCID: PMC4755309 DOI: 10.1016/j.bcp.2014.01.029] [Citation(s) in RCA: 137] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 01/17/2014] [Accepted: 01/22/2014] [Indexed: 01/02/2023]
Abstract
This review covers history underlying the discovery of the molecular mediators of nicotine's effects in the brain and the diversity of the nicotinic acetylcholine receptor (nAChR) subtypes. Models are presented for both their structure and their function as mediators of signal transduction, with special consideration of the differences between the two main subtypes: heteromeric receptors, which are specialized for rapid electrochemical signal transduction, and homomeric α7 receptors, which have come to be implicated in both ionotropic and metabotropic signaling. This review presents perspectives on the pharmacology and therapeutic targeting of nAChRs for the treatment of nicotine dependence or disease.
Collapse
Affiliation(s)
- Roger L Papke
- Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, PO Box 100267, 1200 Newell Drive, Gainesville, FL 32610-0267, USA.
| |
Collapse
|
20
|
Brunzell DH, McIntosh JM, Papke RL. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation. Ann N Y Acad Sci 2014; 1327:27-45. [PMID: 24730978 DOI: 10.1111/nyas.12421] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Preclinical studies suggest that a diversity of nicotinic acetylcholine receptors (nAChRs) with different sensitivities to nicotine may contribute to tobacco addiction. Using rodent intravenous nicotine self-administration as a preclinical model with good predictive validity for therapeutic efficacy for tobacco cessation, investigators have identified heteromeric α6β2* and homomeric α7 nAChRs as promising novel therapeutic targets to promote smoking abstinence (*denotes possible assembly with other subunits). The data suggest that diverse strategies that target these subclasses of nAChRs, namely inhibition of α6β2* nAChRs and stimulation of α7 nAChRs, will support tobacco cessation. α6β2* nAChRs, members of the high-affinity family of β2* nAChRs, function similarly to α4β2* nAChRs, the primary target of the FDA-approved drug varenicline, but have a much more selective neuroanatomical pattern of expression in catecholaminergic nuclei. Although activation of β2* nAChRs facilitates nicotine self-administration, stimulation of α7 nAChRs appears to negatively modulate both nicotine reinforcement and β2* nAChR function in the mesolimbic dopamine system. Although challenges and caveats must be considered in the development of therapeutics that target these nAChR subpopulations, an accumulation of data suggests that α7 nAChR agonists, partial agonists, or positive allosteric modulators and α6β2* nAChR antagonists, partial agonists, or negative allosteric modulators may prove to be effective therapeutics for tobacco cessation.
Collapse
Affiliation(s)
- Darlene H Brunzell
- Department of Pharmacology and Toxicology, Interdisciplinary Neuroscience Program and Institute for Drug and Alcohol Studies, Virginia Commonwealth University School of Medicine, Richmond, Virginia
| | | | | |
Collapse
|
21
|
Schilaty ND, Hedges DM, Jang EY, Folsom RJ, Yorgason JT, McIntosh JM, Steffensen SC. Acute ethanol inhibits dopamine release in the nucleus accumbens via α6 nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2014; 349:559-67. [PMID: 24643637 DOI: 10.1124/jpet.113.211490] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Electrophysiology and microdialysis studies have provided compelling evidence that moderate to high ethanol concentrations enhance dopamine (DA) neurotransmission in the nucleus accumbens (NAc) through the mesolimbic DA system. However, with fast-scan cyclic voltammetry, short-term exposure to moderate to high doses of ethanol decreases evoked DA release at terminals in the NAc. The aim of this study was to evaluate the involvement of nicotinic acetylcholine receptors (nAChRs) in modulating the effects of ethanol on DA release in the NAc of C57BL/6 mice ex vivo and in vivo. Local stimulation evoked robust, frequency-dependent DA release in the NAc slice preparation, with maximal release at 40 Hz in the shell and 20 Hz in the core. Nicotine decreased DA release in a concentration-dependent (0.01-10 μM) manner in the shell and core, with an IC50 of 0.1 μM ex vivo and 0.5 mg/kg in vivo. Nicotine and ethanol inhibition of DA release was blocked by the α6*-nAChR antagonist α-conotoxins CtxMII and α-CtxMII [H9A; L15A] ex vivo (100 nM) in the core but not the shell. Furthermore, the nonspecific nAChR antagonist mecamylamine (2 mg/kg) blocked the effects of ethanol in the core in vivo. These findings suggest that DA release is inhibited by ethanol via nAChRs in the NAc and that DA modulation by nAChRs differs in the core versus the shell, with α6*-nAChRs affecting DA release in the core but not in the shell.
Collapse
Affiliation(s)
- Nathan D Schilaty
- Department of Psychology and Center for Neuroscience, Brigham Young University, Provo, Utah (N.D.S., D.M.H., E.Y.J., R.J.F., S.C.S.); Vollum Institute, Oregon Health and Science University, Portland, Oregon (J.T.Y.); and Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, Utah (J.M.M.)
| | | | | | | | | | | | | |
Collapse
|
22
|
Papke RL, Horenstein NA, Kulkarni AR, Stokes C, Corrie LW, Maeng CY, Thakur GA. The activity of GAT107, an allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), is regulated by aromatic amino acids that span the subunit interface. J Biol Chem 2013; 289:4515-31. [PMID: 24362025 DOI: 10.1074/jbc.m113.524603] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
GAT107, the (+)-enantiomer of racemic 4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide, is a strong positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptor (nAChR) activation by orthosteric agonists with intrinsic allosteric agonist activities. The direct activation produced by GAT107 in electrophysiological studies is observed only as long as GAT107 is freely diffusible in solution, although the potentiating activity primed by GAT107 can persist for over 30 min after drug washout. Direct activation is sensitive to α7 nAChR antagonist methyllycaconitine, although the primed potentiation is not. The data are consistent with GAT107 activity arising from two different sites. We show that the coupling between PAMs and the binding of orthosteric ligands requires tryptophan 55 (Trp-55), which is located at the subunit interface on the complementary surface of the orthosteric binding site. Mutations of Trp-55 increase the direct activation produced by GAT107 and reduce or prevent the synergy between allosteric and orthosteric binding sites, so that these mutants can also be directly activated by other PAMs such as PNU-120596 and TQS, which do not activate wild-type α7 in the absence of orthosteric agonists. We identify Tyr-93 as an essential element for orthosteric activation, because Y93C mutants are insensitive to orthosteric agonists but respond to GAT107. Our data show that both orthosteric and allosteric activation of α7 nAChR require cooperative activity at the interface between the subunits in the extracellular domain. These cooperative effects rely on key aromatic residues, and although mutations of Trp-55 reduce the restraints placed on the requirement for orthosteric agonists, Tyr-93 can conduct both orthosteric activation and desensitization among the subunits.
Collapse
Affiliation(s)
- Roger L Papke
- From the Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida 32610
| | | | | | | | | | | | | |
Collapse
|
23
|
Colón-Sáez JO, Yakel JL. A mutation in the extracellular domain of the α7 nAChR reduces calcium permeability. Pflugers Arch 2013; 466:1571-9. [PMID: 24177919 DOI: 10.1007/s00424-013-1385-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Revised: 10/11/2013] [Accepted: 10/12/2013] [Indexed: 10/26/2022]
Abstract
The α7 neuronal nicotinic acetylcholine receptor (nAChR) displays the highest calcium permeability among the different subtypes of nAChRs expressed in the mammalian brain and can impact cellular events including neurotransmitter release, second messenger cascades, cell survival, and apoptosis. The selectivity for cations in nAChRs is thought to be achieved in part by anionic residues which are located on either side of the channel mouth and increase relative cationic concentration. Mutagenesis studies have improved our understanding of the role of the second transmembrane domain and the intracellular loop of the channel in ion selectivity. However, little is known about the influence that the extracellular domain (ECD) plays in ion permeation. In the α7 nAChR, it has been found that the ECD contains a ring of ten aspartates (two per subunit) that is believed to face the lumen of the pore and could attract cations for permeation. Using mutagenesis and a combination of electrophysiology and imaging techniques, we tested the possible involvement of these aspartate residues in the calcium permeability of the rat α7 nAChR. We found that one of these residues (the aspartate at position 44) appears to be essential since mutating it to alanine resulted in a decrease in amplitude for both whole cell and single-channel responses and in the complete disappearance of detectable calcium changes in most cells, which indicates that the ECD of the α7 nAChR plays a key role in calcium permeation.
Collapse
Affiliation(s)
- José O Colón-Sáez
- Laboratory of Neurobiology, National Institute of Environmental Health Science, National Institutes of Health, Department of Health and Human Services, PO Box 12233, Research Triangle Park, NC, 27709, USA
| | | |
Collapse
|